Health in Andorra 740 indicators covering health for Andorra. IndicatorLatest Year10-yr change Rank Mean hemoglobin level of children aged 6-59 months 121 2019 down 0.8% 12th Countries with birth registration data that are at least 90 percent 1 2024 unchanged 2nd Ipv vaccine coverage 98 2024 down 1.0% 32nd Tb patients living with hiv receiving art 0 2021 — 141st Hospital beds 25.62 2008 down 20.2% 70th New leprosy case detection rate per 1 000 000 population 0 2024 — 124th Polio vaccine: inactivated second or third-dose polio vaccine (IPVc) 98.0% 2025 — 16th Leprosy registered prevalence rate per 1 000 000 population 0 2024 — 121st Leprosy - Number of new leprosy cases among children 0 2024 — 69th Leprosy - Number of cases registered for treatment 0 2024 — 121st New leprosy child case detection rate (less than 15 years of age) per 0 2024 — 69th Ipv1 number unvaccinated 8.96 2023 up 47.9% 188th Age-standardized prevalence of current tobacco use among persons aged 35.5% 2024 up 0.3% 11th Number of female leprosy new cases 0 2024 — 102nd National smoking ban: NUMBER OF PLACES SMOKE-FREE 5 2022 unchanged 96th Number of prevalent tuberculosis cases 8.6 2014 down 33.8% 183rd Number of new G2D leprosy cases 0 2024 — 86th Leprosy - New leprosy cases with G2D rate per 1 000 000 population 0 2024 — 86th Proportion of total government spending on essential services, health 23.1% 2024 up 4.3% 1st Inflation-adjusted prices for most sold brand of cigarettes: Prices 6.2 2022 up 9.2% 94th Taxes as a % of price: total tax 78.3% 2022 up 39.2% 21st Taxes as a % of price: value added tax 4.3% 2022 up 314.4% 162nd Taxes as a % of price: ad valorem excise 0.0% 2022 — 106th Taxes as a % of price: specific excise 74.0% 2022 up 38.4% 2nd Taxes as a % of price: import duties 0.0% 2022 — 37th Taxes as a % of price: other taxes 0.0% 2022 down 100.0% 56th Inflation-adjusted prices for most sold brand of cigarettes: Price in 3.65 2022 up 5.8% 167th Physical activity policies for activie societies 20 2023 up 100.0% 2nd Physical activity policies focused on active systems 20 2023 unchanged 5th Midwifery personnel 18 2024 unchanged 125th Share of one year olds who received the final dose of pneumococcal vac 96 2024 up 3.2% 14th Diphtheria tetanus pertussis vaccine vs pneumococcal vaccine coverage 96 2024 up 3.2% 14th Share of deaths registered 54.73 2019 — 135th Affordability - percentage of GDP per capita required to purchase 0.95 2022 up 9.2% 168th Japanese encephalitis - number of reported cases 0 2021 — 19th Infant mortality rates 1.8 2018 down 21.7% 23rd Number of new leprosy cases with G2D among children 0 2024 — 35th Most sold brand of cigarettes - price in currency reported 3.65 2020 up 52.1% 170th Most sold brand of cigarettes - taxes as a % of price - total tax 0.8% 2020 up 34.5% 25th Most sold brand of cigarettes - taxes as a % of price - ad valorem 0.0% 2020 down 100.0% 109th Most sold brand of cigarettes - taxes as a % of price - other taxes 0.0% 2020 — 41st Most sold brand of cigarettes - taxes as a % of price - import duties 0.0% 2020 down 100.0% 33rd Most sold brand of cigarettes - taxes as a % of price - value added 0.0% 2020 up 300.0% 156th Most sold brand of cigarettes - taxes as a % of price - specific 0.7% 2020 up 7,300.0% 1st Most sold brand of cigarettes - price in US$ at official exchange 4.32 2020 up 38.0% 63rd Import of environmentally sound technologies 44.80 million 2018 up 17.2% 151st Export of environmentally sound technologies 1.51 million 2018 down 55.3% 144th Pcv3 number unvaccinated 26.88 2023 down 38.3% 141st Number of non-autochthonous leprosy cases 0 2024 — 47th HPV immunization coverage estimates among primary target cohort (9-14) 90.0% 2025 up 83.7% 18th Tuberculosis - new and relapse cases 3 2011 down 70.0% 184th Physiotherapists 198 2024 up 115.2% 76th Generalist medical practitioners 109 2024 up 53.5% 100th Average of 13 International Health Regulations core capacity scores 29.04 2017 down 19.3% 139th New cases: pulmonary smear-negative 3 2012 up 50.0% 173rd Total number of notified TB cases 6 2014 down 14.3% 182nd The number of people with susceptibility test result for rifampicin 2 2021 — 143rd Specialist medical practitioners 310 2024 up 80.2% 85th New cases: pulmonary smear unknown/not done 0 2012 — 109th Smear-positive tuberculosis treatment-success rate 100.0% 2011 unchanged 1st ← Previous Page 12 of 13 Next →